Leaflet ALFUZOSINA AUROBINDO 10mg prolonged-release tablets

Product code:
W67849001
Quantity:
30
Indicated for:
benign prostatic hyperplasia
Route of administration:
oral
Substance:
alfuzosin (alpha-1 blocker)
ATC
G04CA01 — Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Alpha-adrenoreceptor antagonists
Alfuzosin is a medication used to treat symptoms associated with benign prostatic hyperplasia (BPH), a condition characterized by an enlarged prostate that can cause difficulty urinating. Alfuzosin belongs to the class of alpha-blockers and works by relaxing the smooth muscles in the prostate and bladder neck, making it easier to urinate.

It is taken orally, usually once daily after a meal, to reduce the risk of side effects. Beneficial effects may be noticed within a few days of starting treatment.

Common side effects include dizziness, fatigue, headache, or orthostatic hypotension (a drop in blood pressure when standing up). Patients are advised to avoid sudden movements to prevent dizziness. Alfuzosin is contraindicated in patients with severe liver impairment or those taking other medications that may interact with it. It should be used as directed by a doctor.

General data about ALFUZOSINA AUROBINDO 10mg

Substance:
alfuzosin
Date of latest medicines list:
01-09-2021
Product code:
W67849001
Concentration:
10mg
Pharmaceutical form:
prolonged-release tablets
Quantity:
30
Product type:
Generic medicine
Prescription status:
P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

Manufacturer:
APL SWIFT SERVICES (MALTA) LIMITED - MALTA
Holder:
AUROBINDO PHARMA ROMANIA S.R.L. - ROMANIA
Number:
9539/2016/01
Shelf life:
3 years

Concentrations available for alfuzosin

  • 10mg
  • 2.5mg
  • 5mg